Generic Drug Industry Market Research & Statistics

 
  • Currently 5/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
11 votes
Share

Global Generic Drug Industry

 

The global generic drug market should grow at a compound annual growth rate of 15% over five years to be worth just under $169 billion in 2014, according to a report from BCC Research.

 

The generic drug industry covers the marketing and sale of medication containing the same active ingredients and dosages as brand-name drugs manufactured by the pharmaceutical industry. Drugs can be prescribed under their chemical name without specifying a particular pharmaceutical brand or company. A key benefit of generic drugs is that they usually cost a fraction of the price of brand-name drugs, as much as 80% to 85% less according to the US Food and Drug Administration. For example, Glucotrol, a drug used in the treatment of diabetes, represents a monthly cost to patients of between $42 and $84 for 10 mg tablets; however, the drug’s generic version, Glipizide, costs up to 10 times less at between $4 and $8 per month.

 

Generic drugs are under the same governance as brand-name drugs and must adhere to the same standards. When brand-name drugs come off patent, the market is opened up to generic versions. Patent protection generally protects a drug’s intellectual property rights for about 20 years, but as the patent is effective from the clinical trial stage, the actual time the drug is on the market can be far less, often between 10 and 14 years. After a patent expires, pharmaceutical companies come under fierce pricing pressure due to competition from their less-expensive generic counterparts.

 

Drugs coming off patent through 2014 represent a forecast annual loss of $136 billion, according to industry analysis. Generics help reduce government spending on healthcare, accounting in part for a near 5% decrease in US drug spending, reports the FDA. The FDA acts as a governing body for generic drugs to enforce maximum standards of variation with brand-name drugs. However, in an 11-year study, variation in absorption of branded and generic drugs was found to be as little as 3.5%. Such negligible variation could equally exist in a comparison of two branded drugs.

 

Value of Products at risk to Generic Competition - 2010 to 2014 

 

 

Best-Selling Generic Drugs

 

Generic drugs took all of the top-10 spots for the most-prescribed drugs in the US last year, as ranked by the IMS Institute for Healthcare Informatics. Only three brand-name drugs ranked in the top 25, highlighting the strong foothold secured by generics.

 

Possibly further boosting future sales is the looming patent expiration of several of the pharmaceutical world’s star prescription brand-name drugs, for which generics are poised to claim sizeable market share. Top generic drugs to enter the market this year are expected to be Methylphenidate (an attention deficit hyperactivity disorder drug taking over from Concerta) and Levofloxacin (a copy of antibiotic Levaquin). In October 2011 Zyprexa, used to treat bipolar disorder and schizophrenia, will come off patent leaving the door open for generic Olanzapine. November 2011 will see a top selling drug in the US, Pfizer’s Lipitor used to treat cholesterol, come off patent; Lipitor represents annual profit from sales of $10 billion, reports the New York Times.

 

In March 2012, depression drug Lexapro will come off patent, leaving room for generic Escitalopram. In the same month generic Quetiapine will be poised to compete with antipsychotic Seroquel. Clopidogrel, used to prevent blood clots and ward off strokes and heart attacks, will be able to take some of Plavix’s market share.

 

Other generics set to take over from brand-name drugs include:

  • Fenofibrate based on the cholestrol drug Tricor
  • Montelukast based on the asthma and allergy treatment Singulair
  • Pioglitazone based on the diabetic drug Actos
  • Valsartan based on the high blood pressure medication Diovan

 

 

 Major US Drug Patent Expiries (2011)

 

Drug (Company) Disease US Sales in 2009
Lipitor (Pfizer) High Cholesterol $7,1 Bn
Plavix (BMS/Sanofi-Aventis) Blood clots $5,7 Bn
Advair Diskus (GlaxoSmithKline) Asthma/COPD $4,6 Bn
Zyprexa (Eli Lilly) Antipsychotic $2,7 Bn
Levaquin (J&J) Infections $1,5 Bn

 

Source: IMS Health

 

 

Industry Leaders

 

BCC Research shows Teva Pharmaceutical Industries to hold just under 20% of the global generic drugs market, followed by Sandoz, with 10% of the market. In joint third place are Watson and Mylan, with 6% each. Together, Teva, Sandoz, Watson and Mylan hold a combined 40% share of the global market.

 

 

Market Outlook

 

The generic drug market is gaining increasing ground over brand-name pharmaceuticals, with the FDA reporting that generics account for more than 70% of prescription drugs in the US. The US market for generic drugs is forecast to show more than 10% CAGR, reaching $54 billion in 2014. Japan is likely to see over 12% growth to exceed $9.5 billion in 2014, reports BCC Research.

 

 

Generic Drugs: Market Share Forecasts for Developed Markets to 2015
 

 

 

Leading Associations

 

ReportLinker.com offers immediate download access to top market reports & statistics on the Generic Drug Industry from trusted sources.
1-10 of about 200 reports

Global Generic Drug Markets Forecast

  • January 2013
    24 pages
  • Generic Drug  

  • China  

    World  

View report >

Generic Drug Industry in the US

  • September 2014
    23 pages
  • Generic Drug  

    Generics  

  • United States  

View report >

Generic Drugs Markets in Brazil

  • December 2013
    44 pages
  • Generic Drugs  

  • Brazil  

    South America  

View report >

Generic Drug Industry in India Forecast

  • December 2013
    10 pages
  • Generic Drug  

  • India  

View report >

Generic Drug Industry in China

  • January 2013
    6 pages
  • Generic Drug  

  • China  

View report >

Biosimilars Industry in the US

  • January 2015
    8 pages
  • Biosimilars  

    Pharmacy  

  • United States  

View report >

The future of the Biosimilars Industry in the US

  • January 2015
    2 pages
  • Biosimilars  

  • United States  

    North America  

View report >

Biosimilars Market Forecast in Europe

  • September 2014
    2 pages
  • Biosimilars  

    Drug  

  • Europe  

    Spain  

    World  

View report >

Generic Drug Statistics

  • July 2014
    14 pages
  • Generic Drug  

  • India  

    United States  

    Russian Federat  

View report >

Generics Markets in the US

  • July 2014
    12 pages
  • Generics  

  • United States  

View report >


About 600 reports

Purchase Reports From Reputable Market Research Publishers
(From $ 125 - $ 3 500)

Patent Cliff and the Future of Generics in Asia : Trends that will Impact the Market in the Short Term

Patent Cliff and the Future of Generics in Asia : Trends that will Impact the Market in the Short Term

  • $ 3 500
  • Industry report
  • December 2014
  • by Frost & Sullivan

Executive Summary •The generic drug manufacturers in Asia have started looking beyond patent cliff to drive growth. As less drugs are expected to go off patent in 2015-2017, the manufacturers are adopting ...

2015 Market Research Report On Global Biologics And Bio ...

February 2015 $ 2 600

The Generic Drugs Market: 2015 - 2030 - Opportunities, ...

February 2015 $ 2 500

Generic Drugs Market In Japan 2015-2019

February 2015 $ 2 500

Generics: World Market Overview (market Size, Segmentat ...

December 2014 $ 1 495

Generic Pharmaceuticals Global - Industry Report

March 2015 $ 1 668

Serbia Pharmaceuticals And Healthcare Industry Update Q ...

January 2015 $ 1 300

Mexico Pharmaceuticals And Healthcare Industry Update Q ...

January 2015 $ 1 300

Philippines Pharmaceuticals And Healthcare Industry Upd ...

December 2014 $ 1 300

Us Generic Drug Market Outlook 2018

February 2015 $ 1 200


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.